M&A / Deals RA Capital targets China with latest SPAC deal BioPharma DiveThe prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.M&A / DealsRead full story pharminent March 24, 2026 (Last updated: March 25, 2026) BioPharma Dive The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing. M&A / DealsRead full story Post navigation Previous: Immutrin raises $87M to advance drug for progressive heart diseaseNext: Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
